PMA device
Pathway ANTI-HCR-2/NCU (4B5) Rabbit Monoclonal Primary Antibody
Ventana Medical Systems, Inc. · System, Test, Her-2/Neu, Ihc (MVC, Class III) · First FDA decision Nov 28, 2000, newest Nov 28, 2000Breast cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Pathway ANTI-HCR-2 NCU"
MAUDE reports
0
Brand "Pathway ANTI-HCR-2 NCU", since 2015
PubMed studies
0
Mentioning "Pathway ANTI-HCR-2 NCU"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Pathway ANTI-HCR-2/NCU (4B5) Rabbit Monoclonal Primary Antibody
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P990081 · Decided Nov 28, 2000 · 351 days after receipt
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Pathway ANTI-HCR-2 NCU", any status and sponsor, newest update first.
No registered device study names "Pathway ANTI-HCR-2 NCU".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Pathway ANTI-HCR-2 NCU", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MVC
12 reports: 4 malfunction, 5 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2716-2011 · Started May 16, 2011 · Posted by FDA Jul 1, 2011
Reason given: The recall was initiated because Ventana Medical Systems, Inc. (Ventana), has identified the presence of precipitate in some DAB chromogen dispensers in two lots of ultraView Universal DAB Detection Kit (part number 760-500, lot A05885 and lot B00988) and one lot of iView DAB Detection Kit (part number 760-091, lot...
Cause as FDA categorized it: Pending · Device type: Immunohistochemistry Antibody Assay, Estrogen Receptor (MYA)
2 more recall records with a free account
Published research
The most relevant PubMed records for "Pathway ANTI-HCR-2 NCU"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MVC.
- PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2026
- HerceptestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Bond Oracle HER2 Ihc SystemLeica Biosystems · PMA 2014
- Hercep TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2012
- PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2025
- Hercap TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Pathway Her 2 (Clone CB11)Ventana Medical Systems, Inc. · PMA 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.